Results 1 to 10 of about 42,131 (286)

Endoplasmic reticulum stress mediates homocysteine-induced hypertrophy of cardiac cells through activation of cyclic nucleotide phosphodiesterase 1C [PDF]

Acta Biochimica et Biophysica Sinica, 2022
Although the association of elevated homocysteine level with cardiac hypertrophy has been reported, the molecular mechanisms by which homocysteine induces cardiac hypertrophy remain inadequately understood.
Sun Wentao, Zhou Yang, Xue Hongmei, Hou Haitao, He Guowei, Yang Qin   +5 more
doaj   +2 more sources

Investigation of an 18F-labelled Imidazopyridotriazine for Molecular Imaging of Cyclic Nucleotide Phosphodiesterase 2A [PDF]

Molecules, 2018
Specific radioligands for in vivo visualization and quantification of cyclic nucleotide phosphodiesterase 2A (PDE2A) by positron emission tomography (PET) are increasingly gaining interest in brain research.
Susann Schröder, Barbara Wenzel, Winnie Deuther-Conrad, Rodrigo Teodoro, Mathias Kranz, Matthias Scheunemann, Ute Egerland, Norbert Höfgen, Detlef Briel, Jörg Steinbach, Peter Brust   +10 more
doaj   +2 more sources

Identification and Localization of the Cyclic Nucleotide Phosphodiesterase 10A in Bovine Testis and Mature Spermatozoa. [PDF]

PLoS ONE, 2016
In mammals, adenosine 3', 5'-cyclic monophosphate (cAMP) is known to play highly important roles in sperm motility and acrosomal exocytosis. It is known to act through protein phosphorylation via PRKA and through the activation of guanine nucleotide ...
Serge Goupil, Loïze Maréchal, Hassan El Hajj, Marie-Ève Tremblay, François J Richard, Pierre Leclerc   +5 more
doaj   +2 more sources

AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B [PDF]

Nature Communications, 2016
The diabetes drug Metformin decreases hepatic glucose production and activates AMP-activated protein kinase (AMPK). Here the authors provide evidence that AMPK activation antagonizes glucagon signalling by activating PDE4B, lowering cAMP levels and ...
M. Johanns, Y.-C. Lai, M.-F. Hsu, R. Jacobs, D. Vertommen, J. Van Sande, J. E. Dumont, A. Woods, D. Carling, L. Hue, B. Viollet, M Foretz, M H Rider   +12 more
doaj   +2 more sources

PDE Inhibitors and Autophagy Regulators Modulate CRE-Dependent Luciferase Activity in Neuronal Cells from the Mouse Suprachiasmatic Nucleus [PDF]

Molecules
Background: Signaling pathways like those depending on cAMP/PKA, calcium/calmodulin/CaMK, MEK-1/MAPK or PI3K/Akt have been described to modulate suprachiasmatic nucleus (SCN) neuronal signaling via influencing transcription factors like CREB.
Erik Maronde, Abdelhaq Rami
doaj   +2 more sources

Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. [PDF]

PLoS Neglected Tropical Diseases, 2017
Reliance on just one drug to treat the prevalent tropical disease, schistosomiasis, spurs the search for new drugs and drug targets. Inhibitors of human cyclic nucleotide phosphodiesterases (huPDEs), including PDE4, are under development as novel drugs ...
Thavy Long, Liliana Rojo-Arreola, Da Shi, Nelly El-Sakkary, Kurt Jarnagin, Fernando Rock, Maliwan Meewan, Alberto A Rascón, Lin Lin, Katherine A Cunningham, George A Lemieux, Larissa Podust, Ruben Abagyan, Kaveh Ashrafi, James H McKerrow, Conor R Caffrey   +15 more
doaj   +2 more sources

Cyclic nucleotide phosphodiesterases [PDF]

Journal of Allergy and Clinical Immunology, 2001
Cyclic nucleotide second messengers (cAMP and cGMP) play a central role in signal transduction and regulation of physiologic responses. Their intracellular levels are controlled by the complex superfamily of cyclic nucleotide phosphodiesterase (PDE) enzymes. Continuing advances in our understanding of the molecular pharmacology of these enzymes has led
David M. Essayan
openalex   +4 more sources

Cyclic nucleotide phosphodiesterase 1 and vascular aging. [PDF]

Clin Sci (Lond), 2015
VSMCs (vascular smooth muscle cells) play critical roles in arterial remodelling with aging, hypertension and atherosclerosis. VSMCs exist in diverse phenotypes and exhibit phenotypic plasticity, e.g. changing from a quiescent/contractile phenotype to an active myofibroblast-like, often called ‘synthetic’, phenotype.
Yan C.
europepmc   +5 more sources

Novel Radioligands for Cyclic Nucleotide Phosphodiesterase Imaging with Positron Emission Tomography: An Update on Developments Since 2012 [PDF]

Molecules, 2016
Cyclic nucleotide phosphodiesterases (PDEs) are a class of intracellular enzymes that inactivate the secondary messenger molecules, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
Susann Schröder, Barbara Wenzel, Winnie Deuther-Conrad, Matthias Scheunemann, Peter Brust   +4 more
doaj   +2 more sources

Inhibitors of cyclic nucleotide phosphodiesterases produced by streptomyces. IV. Inhibition of cyclic nucleotide phosphodiesterases by reticulol.

Agricultural and Biological Chemistry, 1977
Inhibition mechanism of rat cerebral cortex cyclic nucleotide phosphodiesterases (PDE) by reticulol was investigated. The inhibition of PDE by reticulol was not reduced in the presence of excess PDE activating factor (PAF) or/and Ca2+ ion. Reticulol showed lower Ki values for Ca2+-PAF dependent PDE than for Ca2+ independent PDE.
Yoshio Furutani, TOMIO TAKEUCHI, HAMAO UMEZAWA   +2 more
openalex   +4 more sources